PUBLISHER: Roots Analysis | PRODUCT CODE: 1919793
PUBLISHER: Roots Analysis | PRODUCT CODE: 1919793
As per Roots Analysis, the Japan digital therapeutics market is estimated to grow from USD 0.15 billion in 2026 to USD 1.13 billion by 2035 at a CAGR of 23.6% during the forecast period, 2026-2035.

Digital therapeutics are software or mobile app-based solutions that have been clinically validated to help prevent, treat, or manage diseases or clinical conditions. They have shown to be effective in addressing a variety of disorders, including lifestyle-related diseases, mental health problems, neurological disorders, and substance use disorders. Interestingly, such solutions usually employ evidence based and clinically validated software or technologies, in order to capture real-time / real world patient data and provide improved curative response. Further, these real-world outcomes generated by digital therapeutics may be used to optimize outcomes at the individual patient and population levels.
Considering the ongoing digitization efforts and transformation of the healthcare sector, digital therapeutics have garnered significant attention from industry stakeholders and investors alike. Additionally, government organizations have actively undertaken initiatives, such as enactment of legislation, publishing laws and establishment of regulations in the digital therapeutics industry.
The rising recognition of the advantages of digital therapeutics among healthcare providers, payers, and employers, along with pharmaceutical companies' growing interest in investing in treatment and care-related applications, is driving the market expansion.
It is important to highlight that Japan's digital therapeutics (DTx) market is flourishing due to its rapidly aging population, supportive regulatory reforms, and expanding national health insurance coverage for approved products. This drives demand for innovative solutions to manage chronic diseases, such as diabetes, hypertension, and mental health disorders through remote monitoring and behavioral interventions. Thus, in the future, ongoing regulatory progress and technological developments enable Japan to be at the forefront of global DTx innovation.
Growth Drivers: Strategic Enablers of Market Expansion
Aging demographics, with over 20% of the population above 65, fuel demand for DTx in managing chronic conditions like diabetes, hypertension, mental health issues, and cardiovascular diseases. Regulatory easing for low-risk Software as a Medical Device (SaMD) accelerates approvals and market entry, while advancements in AI, machine learning, and wearables enable personalized interventions. Integration with national health insurance and electronic health records, plus partnerships among hospitals, insurers, and developers, boosts adoption across urban and rural areas.
Market Challenges: Critical Barriers Impeding Progress
Only a few DTx products highlight limited national health insurance coverage, slowing widespread use. Clinician and patient awareness remains low, requiring education to drive acceptance, alongside concerns over data privacy and skilled personnel shortages. Dependence on regulatory reforms and reimbursement pathways means growth hinges on synchronized policy advancements.
Metabolic Disorder: Leading Market Segment
In terms of type of therapeutic area, the Japan digital therapeutics market is segmented across cardiovascular disorders, chronic pain, mental health problems, metabolic disorders, neurological disorders, respiratory disorders, sleep disorders, substance use disorders, and other disorders. Currently, metabolic disorders segment captures around 25% of the overall market share, followed by mental health disorders. The higher share of XX can be attributed to a higher prevalence of the disease and favorable regulatory environments. The increasing elderly population and the rise in chronic diseases create a demand for digital therapeutics aimed at changing behavior and ensuring adherence.
B2B Business Model: Dominating Market Segment
In terms of business model adopted, the Japan digital therapeutics market is segmented across B2B and B2C business model. Currently, majority (~65%) of the market share is held by B2B business model. This is a result of strategic collaborations with healthcare facilities, insurance providers, and businesses that facilitate widespread implementation and integration of reimbursement.
Type of Solution
Type of Therapy
Purpose of Solution
Type of Business Model
Target Therapeutic Area
COMPLEMENTARY BENEFITS